36
Participants
Start Date
June 30, 2013
Primary Completion Date
April 30, 2015
Study Completion Date
April 30, 2015
Dalbavancin
Intravenous dalbavancin given at 15 mg/kg (not to exceed 1000 mg) for patients ≥5 years of age, and 25 mg/kg for patients \<5 years of age.
Columbia University, New York
Tallin's Children Hospital Pediatric Clinic, Tallinn
Duke Medical Center, Durham
University of Louisville, Louisville
Pediatric Pharmacology, Toledo
University of Michigan Medical Center, Ann Arbor
Tartu University Hospital Anesthesiology & Intensive Care, Tartu
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
University Arkansas Medical Center, Little Rock
Texas Children's Hospital - Clinical Care Center, Houston
University of California, San Diego, San Diego
Connecicut Children's Hospital, Hartford
Durata Therapeutics Inc., an affiliate of Allergan plc
INDUSTRY